Eli Lilly and Company - Product Releaseshttp://newsroom.lilly.com/newslist.cfm?sh_auth=767441604.0.0.9c90276473a65356550854f18e998096en-usShareholder.com RSS FeedCymbalta(R) Significantly Reduced Chronic Low Back Pain in New Studyhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=442413Wed, 03 Feb 2010 13:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=442413Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New StudyNew Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCIhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=434208Tue, 05 Jan 2010 14:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=434208New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCIExenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Studyhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=430179Tue, 15 Dec 2009 13:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=430179Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 StudyFDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adultshttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=429876Mon, 14 Dec 2009 13:30:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=429876FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in AdultsBears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaignhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=429619Fri, 11 Dec 2009 15:15:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=429619Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes CampaignLilly Announces the First 300-unit Vial of Insulinhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=428632Mon, 07 Dec 2009 21:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=428632Lilly Announces the First 300-unit Vial of InsulinFDA Approves Lilly's Zyprexa for Two Adolescent Indicationshttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=428395Fri, 04 Dec 2009 21:30:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=428395FDA Approves Lilly's Zyprexa for Two Adolescent IndicationsNew Web Site Fills in the Missing Pieces That May Be Hindering Recovery From Depressionhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=427049Mon, 30 Nov 2009 20:30:08 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=427049New Web Site Fills in the Missing Pieces That May Be Hindering Recovery From DepressionFDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorderhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=426866Mon, 30 Nov 2009 13:00:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=426866FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety DisorderNew Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCIhttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=425121Wed, 18 Nov 2009 18:11:00 GMThttp://newsroom.lilly.com/releasedetail.cfm?ReleaseID=425121New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI